Pharmaceutical Marketing
5 articles on Pharmaceutical Marketing, researched and written by the Shotlee Editorial Team from primary sources.
Ozempic Maker Novo Nordisk Sues Eli Lilly Over 'Materially Misleading' Ads
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging deceptive advertising regarding weight-loss drugs. This legal battle highlights the intense competition between semaglutide and tirzepatide.
9 min read
Jim Cramer on Eli Lilly Amid Rival's GLP-1 Lawsuit
Jim Cramer weighs in on Eli Lilly's position in the GLP-1 market following a lawsuit from competitor Novo Nordisk, analyzing the situation for investors.
7 min read
Ozempic Culture: Why Medical Weight Loss Needs Better Guardrails
As semaglutide medications become ubiquitous, we must balance their life-saving cardiovascular benefits with the dangers of normalizing extreme thinness and disordered eating behaviors.
7 min read
Monster of 2025: GLP-1 Promotions
The year 2025 has seen a relentless barrage of ads promoting GLP-1 medications for weight loss, often bypassing FDA approvals and focusing on cosmetic benefits. Despite regulations limiting their use to specific medical conditions, telehealth companies push compounded versions aggressively. This trend threatens to undermine the body positivity movement by exploiting insecurities for profit.
5 min read
Black Friday Promotion of Weight-Loss Drugs Sparks Worries
Experts in eating disorders express alarm over the swift introduction of GLP-1 weight-loss drugs through telehealth platforms and intense social media promotions by certain firms. One instance highlighted references to restrictive Australian regulations hindering detailed medication info for buyers. The Australia and New Zealand Academy for Eating Disorders fears such tactics might appeal to those who don't require the drugs.
5 min read